ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lilly and Purdue sign R&D agreement

by Rick Mullin
July 17, 2017 | APPEARED IN VOLUME 95, ISSUE 29

[+]Enlarge
Credit: Purdue
Lilly will work with Purdue researchers on drug delivery and predictive modeling.
Credit: Purdue
Lilly will work with Purdue researchers on drug delivery and predictive modeling.

Eli Lilly & Co. and Purdue University have formed a five-year pact to develop injectable drug delivery technology and models to predict the therapeutic outcomes of new medicines. Lilly will pay up to $52 million over the term of the contract, making the deal Purdue’s largest collaboration with a single company. Purdue researchers in natural and physical sciences, engineering, and veterinary medicine will work with Lilly. Last year the university announced a plan to invest $250 million in life sciences research. Purdue President Mitchell E. Daniels Jr. is the former head of Lilly’s North American drug operation.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment